Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer
Abstract Ovarian cancer is the most lethal gynecological malignancy. Most patients are diagnosed at an advanced stage with widespread peritoneal dissemination and ascites. Bispecific T‐cell engagers (BiTEs) have demonstrated impressive antitumor efficacy in hematological malignancies, but the clinic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202204654 |
| _version_ | 1797825230213742592 |
|---|---|
| author | Guochuang Chen Leli Zeng Bo Bi Xiuyu Huang Miaojuan Qiu Ping Chen Zhi‐Ying Chen Yulong He Yihang Pan Yu Chen Jing Zhao |
| author_facet | Guochuang Chen Leli Zeng Bo Bi Xiuyu Huang Miaojuan Qiu Ping Chen Zhi‐Ying Chen Yulong He Yihang Pan Yu Chen Jing Zhao |
| author_sort | Guochuang Chen |
| collection | DOAJ |
| description | Abstract Ovarian cancer is the most lethal gynecological malignancy. Most patients are diagnosed at an advanced stage with widespread peritoneal dissemination and ascites. Bispecific T‐cell engagers (BiTEs) have demonstrated impressive antitumor efficacy in hematological malignancies, but the clinical potency is limited by their short half‐life, inconvenient continuous intravenous infusion, and severe toxicity at relevant therapeutic levels in solid tumors. To address these critical issues, the design and engineering of alendronate calcium (CaALN) based gene‐delivery system is reported to express therapeutic level of BiTE (HER2×CD3) for efficient ovarian cancer immunotherapy. Controllable construction of CaALN nanosphere and nanoneedle is achieved by the simple and green coordination reactions that the distinct nanoneedle‐like alendronate calcium (CaALN‐N) with a high aspect ratio enabled efficient gene delivery to the peritoneum without system in vivo toxicity. Especially, CaALN‐N induced apoptosis of SKOV3‐luc cell via down‐regulation of HER2 signaling pathway and synergized with HER2×CD3 to generate high antitumor response. In vivo administration of CaALN‐N/minicircle DNA encoding HER2×CD3 (MC‐HER2×CD3) produces sustained therapeutic levels of BiTE and suppresses tumor growth in a human ovarian cancer xenograft model. Collectively, the engineered alendronate calcium nanoneedle represents a bifunctional gene delivery platform for the efficient and synergistic treatment of ovarian cancer. |
| first_indexed | 2024-03-13T10:50:57Z |
| format | Article |
| id | doaj.art-1f86e3085a54490893f6614fecec525e |
| institution | Directory Open Access Journal |
| issn | 2198-3844 |
| language | English |
| last_indexed | 2024-03-13T10:50:57Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj.art-1f86e3085a54490893f6614fecec525e2023-05-17T13:02:05ZengWileyAdvanced Science2198-38442023-05-011014n/an/a10.1002/advs.202204654Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian CancerGuochuang Chen0Leli Zeng1Bo Bi2Xiuyu Huang3Miaojuan Qiu4Ping Chen5Zhi‐Ying Chen6Yulong He7Yihang Pan8Yu Chen9Jing Zhao10Syno Minicircle Biotechnology Shenzhen 518055 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaSyno Minicircle Biotechnology Shenzhen 518055 P. R. ChinaSyno Minicircle Biotechnology Shenzhen 518055 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaMaterdicine Lab School of Life Sciences Shanghai University Shanghai 200444 P. R. ChinaPrecision Medicine Center Scientific Research Center The Seventh Affiliated Hospital of Sun Yat‐sen University Shenzhen 518107 P. R. ChinaAbstract Ovarian cancer is the most lethal gynecological malignancy. Most patients are diagnosed at an advanced stage with widespread peritoneal dissemination and ascites. Bispecific T‐cell engagers (BiTEs) have demonstrated impressive antitumor efficacy in hematological malignancies, but the clinical potency is limited by their short half‐life, inconvenient continuous intravenous infusion, and severe toxicity at relevant therapeutic levels in solid tumors. To address these critical issues, the design and engineering of alendronate calcium (CaALN) based gene‐delivery system is reported to express therapeutic level of BiTE (HER2×CD3) for efficient ovarian cancer immunotherapy. Controllable construction of CaALN nanosphere and nanoneedle is achieved by the simple and green coordination reactions that the distinct nanoneedle‐like alendronate calcium (CaALN‐N) with a high aspect ratio enabled efficient gene delivery to the peritoneum without system in vivo toxicity. Especially, CaALN‐N induced apoptosis of SKOV3‐luc cell via down‐regulation of HER2 signaling pathway and synergized with HER2×CD3 to generate high antitumor response. In vivo administration of CaALN‐N/minicircle DNA encoding HER2×CD3 (MC‐HER2×CD3) produces sustained therapeutic levels of BiTE and suppresses tumor growth in a human ovarian cancer xenograft model. Collectively, the engineered alendronate calcium nanoneedle represents a bifunctional gene delivery platform for the efficient and synergistic treatment of ovarian cancer.https://doi.org/10.1002/advs.202204654alendronatebispecific T‐cell engagergene deliveryimmunotherapyovarian cancer |
| spellingShingle | Guochuang Chen Leli Zeng Bo Bi Xiuyu Huang Miaojuan Qiu Ping Chen Zhi‐Ying Chen Yulong He Yihang Pan Yu Chen Jing Zhao Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer Advanced Science alendronate bispecific T‐cell engager gene delivery immunotherapy ovarian cancer |
| title | Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer |
| title_full | Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer |
| title_fullStr | Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer |
| title_full_unstemmed | Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer |
| title_short | Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer |
| title_sort | engineering bifunctional calcium alendronate gene delivery nanoneedle for synergistic chemo immuno therapy against her2 positive ovarian cancer |
| topic | alendronate bispecific T‐cell engager gene delivery immunotherapy ovarian cancer |
| url | https://doi.org/10.1002/advs.202204654 |
| work_keys_str_mv | AT guochuangchen engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT lelizeng engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT bobi engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT xiuyuhuang engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT miaojuanqiu engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT pingchen engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT zhiyingchen engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT yulonghe engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT yihangpan engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT yuchen engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer AT jingzhao engineeringbifunctionalcalciumalendronategenedeliverynanoneedleforsynergisticchemoimmunotherapyagainsther2positiveovariancancer |